These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 29061751

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Long-acting Neuraminidase Inhibitor Laninamivir Octanoate as Post-exposure Prophylaxis for Influenza.
    Kashiwagi S, Watanabe A, Ikematsu H, Uemori M, Awamura S, Laninamivir Prophylaxis Study Group.
    Clin Infect Dis; 2016 Aug 01; 63(3):330-7. PubMed ID: 27118785
    [Abstract] [Full Text] [Related]

  • 4. Population pharmacokinetics of laninamivir and its prodrug laninamivir octanoate in healthy subjects and in adult and pediatric patients with influenza virus infection.
    Yoshihara K, Ishizuka H, Kubo Y.
    Drug Metab Pharmacokinet; 2013 Aug 01; 28(5):416-26. PubMed ID: 23574886
    [Abstract] [Full Text] [Related]

  • 5. Laninamivir octanoate for post-exposure prophylaxis of influenza in household contacts: a randomized double blind placebo controlled trial.
    Kashiwagi S, Watanabe A, Ikematsu H, Awamura S, Okamoto T, Uemori M, Ishida K.
    J Infect Chemother; 2013 Aug 01; 19(4):740-9. PubMed ID: 23732307
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection.
    Sugaya N, Ohashi Y.
    Antimicrob Agents Chemother; 2010 Jun 01; 54(6):2575-82. PubMed ID: 20368393
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Evaluation of a dry powder delivery system for laninamivir in a ferret model of influenza infection.
    Panozzo J, Oh DY, Margo K, Morton DA, Piedrafita D, Mosse J, Hurt AC.
    Antiviral Res; 2015 Aug 01; 120():66-71. PubMed ID: 26022199
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Single-dose inhaled laninamivir: registered in Japan and its potential role in control of influenza epidemics.
    Sunagawa S, Higa F, Cash HL, Tateyama M, Uno T, Fujita J.
    Influenza Other Respir Viruses; 2013 Jan 01; 7(1):1-3. PubMed ID: 22405585
    [Abstract] [Full Text] [Related]

  • 12. Structural and functional analysis of laninamivir and its octanoate prodrug reveals group specific mechanisms for influenza NA inhibition.
    Vavricka CJ, Li Q, Wu Y, Qi J, Wang M, Liu Y, Gao F, Liu J, Feng E, He J, Wang J, Liu H, Jiang H, Gao GF.
    PLoS Pathog; 2011 Oct 01; 7(10):e1002249. PubMed ID: 22028647
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetic mechanism involved in the prolonged high retention of laninamivir in mouse respiratory tissues after intranasal administration of its prodrug laninamivir octanoate.
    Koyama K, Nakai D, Takahashi M, Nakai N, Kobayashi N, Imai T, Izumi T.
    Drug Metab Dispos; 2013 Jan 01; 41(1):180-7. PubMed ID: 23091189
    [Abstract] [Full Text] [Related]

  • 14. The pharmacokinetic and safety profiles of zanamivir after single and repeat intravenous administration in healthy Japanese males.
    Shida Y, Hara K, Nohda S, Soutome T, Hirama T.
    J Clin Pharm Ther; 2013 Jun 01; 38(3):236-40. PubMed ID: 23489210
    [Abstract] [Full Text] [Related]

  • 15. Assessment of the effects of renal impairment on the pharmacokinetic profile of laninamivir, a novel neuraminidase inhibitor, after a single inhaled dose of its Prodrug, CS-8958.
    Ishizuka H, Yoshiba S, Yoshihara K, Okabe H.
    J Clin Pharmacol; 2011 Feb 01; 51(2):243-51. PubMed ID: 20197485
    [Abstract] [Full Text] [Related]

  • 16. Identification of bioactivating enzymes involved in the hydrolysis of laninamivir octanoate, a long-acting neuraminidase inhibitor, in human pulmonary tissue.
    Koyama K, Ogura Y, Nakai D, Watanabe M, Munemasa T, Oofune Y, Kubota K, Shinagawa A, Izumi T.
    Drug Metab Dispos; 2014 Jun 01; 42(6):1031-8. PubMed ID: 24682756
    [Abstract] [Full Text] [Related]

  • 17. Neuraminidase inhibitors for preventing and treating influenza in children.
    Wang K, Shun-Shin M, Gill P, Perera R, Harnden A.
    Cochrane Database Syst Rev; 2012 Jan 18; 1():CD002744. PubMed ID: 22258949
    [Abstract] [Full Text] [Related]

  • 18. Characterization of drug-resistant influenza virus A(H1N1) and A(H3N2) variants selected in vitro with laninamivir.
    Samson M, Abed Y, Desrochers FM, Hamilton S, Luttick A, Tucker SP, Pryor MJ, Boivin G.
    Antimicrob Agents Chemother; 2014 Sep 18; 58(9):5220-8. PubMed ID: 24957832
    [Abstract] [Full Text] [Related]

  • 19. The safety and efficacy of the long-acting neuraminidase inhibitor laninamivir octanoate hydrate for Inhalation Suspension Set in children under the age of 5 in a post-marketing surveillance.
    Nakano T, Yamaguchi H, Chiba T, Shiosakai K, Chikada S, Matsuoka Y.
    J Infect Chemother; 2021 Oct 18; 27(10):1436-1446. PubMed ID: 34226112
    [Abstract] [Full Text] [Related]

  • 20. Inhaled Laninamivir Octanoate as Prophylaxis for Influenza in Children.
    Nakano T, Ishiwada N, Sumitani T, Uemori M, Isobe K, Laninamivir Prophylaxis Study Group.
    Pediatrics; 2016 Dec 18; 138(6):. PubMed ID: 27940664
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.